Indivior (LSE:INDV), (NASDAQ:INDV) is a pharmaceutical company focused on developing medications to treat addiction and serious mental illnesses. Their work is centered around providing innovative solutions to individuals suffering from opioid dependence, alcohol dependence, and schizophrenia, among other conditions. Their portfolio includes both marketed therapies and a pipeline of products at various stages of development, aimed at addressing unmet medical needs within these therapeutic areas. Indivior operates with the mission to transform addiction from a global human crisis to a recognized and treated chronic disease, striving to expand access to treatment and to support patients in reclaiming their lives. Their commitment to patient-centric healthcare is evident in their ongoing research and development efforts, as well as their educational and support initiatives for patients and healthcare providers.